Trial Profile

X-linked Hypophosphatemia Disease Monitoring Program (XLH-DMP)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Burosumab (Primary)
Indications X-linked dominant hypophosphataemic rickets
Focus Adverse reactions; Therapeutic Use
Acronyms XLH-DMP
Sponsors Ultragenyx Pharmaceutical

Most Recent Events

10 Sep 2024 According to a Kyowa Kirin media release, additional findings will be presented at American Society for Bone and Mineral Research annual meeting in Toronto, held on Sept 27-30.
10 Sep 2024 According to a Kyowa Kirin media release, findings from XLH Disease Monitoring Program (DMP) published in Journal of Bone and Mineral Research (JBMR Plus).
10 Sep 2024 Results of a new analysis showing low levels of full-time employment and impaired work productivity among working age adults, presented in a Kyowa Kirin media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com